Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06483139 · ClinicalTrials.gov registry record
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
A clinical trial of Multiple Myeloma and Acute Kidney Injury, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- 450
- Enrollment target
- 1
- Study location
NCT06483139 is a study of Multiple Myeloma and Acute Kidney Injury that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 450 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06483139, a study of Multiple Myeloma and Acute Kidney Injury, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
Conditions Studied
Interventions
- PROCEDURE Plasma exchange
- DRUG Daratumumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06483139
The ClinicalTrials.gov registry entry for NCT06483139 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Plasma exchange is the first listed.
NCT06483139 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06483139 about?
NCT06483139 is a clinical study titled "Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy". Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
What is the current status of trial NCT06483139?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2024-06-01. Estimated completion is 2026-06-01.
What conditions does trial NCT06483139 study?
This clinical trial studies the following conditions: Multiple Myeloma, Acute Kidney Injury, Light Chain Nephropathy.
What interventions are being tested in trial NCT06483139?
The interventions under investigation include: Plasma exchange (PROCEDURE), Daratumumab (DRUG).
Who is sponsoring clinical trial NCT06483139?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06483139 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.